Equities research analysts predict that Pfizer Inc. (NYSE:PFE) will post $0.56 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Pfizer’s earnings, with the highest EPS estimate coming in at $0.57 and the lowest estimate coming in at $0.53. Pfizer reported earnings per share of $0.47 in the same quarter last year, which indicates a positive year over year growth rate of 19.1%. The company is expected to issue its next earnings report on Tuesday, January 30th.

On average, analysts expect that Pfizer will report full-year earnings of $2.59 per share for the current financial year, with EPS estimates ranging from $2.57 to $2.60. For the next financial year, analysts anticipate that the firm will post earnings of $2.74 per share, with EPS estimates ranging from $2.66 to $2.80. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Pfizer.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 earnings per share.

Several equities analysts recently issued reports on the company. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Saturday, November 25th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price on the stock in a research report on Thursday, November 23rd. Jefferies Group set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Thursday, November 16th. J P Morgan Chase & Co set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Goldman Sachs Group set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $38.66.

In other Pfizer news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock worth $2,136,189,000 after acquiring an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after acquiring an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after acquiring an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock worth $1,253,813,000 after acquiring an additional 1,085,437 shares in the last quarter. 69.89% of the stock is currently owned by institutional investors.

Shares of Pfizer (PFE) traded down $0.29 during mid-day trading on Monday, hitting $36.06. The stock had a trading volume of 14,086,837 shares, compared to its average volume of 19,979,410. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a 1-year low of $30.51 and a 1-year high of $36.78. The firm has a market capitalization of $214,940.00, a P/E ratio of 14.54, a PEG ratio of 2.57 and a beta of 1.01.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.55%. The ex-dividend date was Thursday, November 9th. Pfizer’s payout ratio is 78.53%.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect Pfizer Inc. (PFE) to Post $0.56 EPS” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/04/zacks-brokerages-expect-pfizer-inc-pfe-to-post-0-56-eps.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.